 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xponance Inc. increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN  Free Report) by 37.1% during the second quarter, according to its most recent Form 13F filing with...

Xponance Inc. Increases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

This price move could indicate a change in the trend, and may be a sell signal for investors...

BioMarin Pharmaceutical (BMRN, $89.25) price exceeded its 50-day Moving Average on September 28, 2023

Rothschild Investment Corp IL cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN  Free Report) by 1.0% in the second quarter, Holdings Channel.com reports. The...

Rothschild Investment Corp IL Decreases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN  Get Free Report)s stock had its buy rating reiterated by equities research analysts at Truist Financial in a research report issued...

BioMarin Pharmaceutical (NASDAQ:BMRN) Earns "Buy" Rating from Truist Financial

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting BioMarin to...

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting

Investors in BioMarin Pharmaceutical Inc (BMRN) saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down...

First Week of November 17th Options Trading For BioMarin Pharmaceutical (BMRN)

BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia BioMarin Receives Positive CHMP Opinion in Europe...

BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

BioMarin to Present Innovative Pipeline at R&amp;D Day on September 12th in New York BioMarin to Present Innovative Pipeline at R&amp;D Day on September 12th in New York PR Newswire SAN...

BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York

Logos Global Management LP purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN  Free Report) in the first quarter, according to its most recent filing with the Securities and...

Logos Global Management LP Makes New $14.59 Million Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin to Present Pipeline at Upcoming R&amp;D Day on Tuesday, September 12th BioMarin to Present Pipeline at Upcoming R&amp;D Day on Tuesday, September 12th PR Newswire SAN RAFAEL, Calif...

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Watchers	5,029
52-Wk Low	$80.53
52-Wk High	$117.77

Market Cap	$16.65B
Volume (M)	1.64M
52-Wk High	$117.77
52-Wk Low	$80.53

BMRN Biomarin Pharmaceutical Inc. - Registered Shares

About

Feed

News

Sentiment

Earnings

Fundamentals